Khadija M'Rabet-Bensalah1, Carole E Aubert1, Michael Coslovsky2, Tinh-Hai Collet3,4, Christine Baumgartner1, Wendy P J den Elzen5, Robert Luben6, Anne Angelillo-Scherrer2,7, Drahomir Aujesky1, Kay-Tee Khaw6, Nicolas Rodondi1. 1. Department of General Internal Medicine, Inselspital, University Hospital of Bern, Bern, Switzerland. 2. Department of Clinical Research, Clinical Trial Unit (CTU), University of Bern, Bern, Switzerland. 3. Service of Endocrinology, Diabetes and Metabolism, University Hospital of Lausanne, Lausanne, Switzerland. 4. University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. 5. Department of Public Health and Primary Care and Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands. 6. Department of Public Health and Primary Care, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. 7. University Clinic of Hematology and Central Hematology Laboratory, Inselspital, University Hospital of Bern, Bern, Switzerland.
Abstract
OBJECTIVE AND BACKGROUND: Anaemia and thyroid dysfunction are common and often co-occur. Current guidelines recommend the assessment of thyroid function in the work-up of anaemia, although evidence on this association is scarce. PATIENTS AND METHODS: In the 'European Prospective Investigation of Cancer' (EPIC)-Norfolk population-based cohort, we aimed to examine the prevalence and type of anaemia (defined as haemoglobin <13 g/dl for men and <12 g/dl for women) according to different thyroid function groups. RESULTS: The mean age of the 8791 participants was 59·4 (SD 9·1) years and 55·2% were women. Thyroid dysfunction was present in 437 (5·0%) and anaemia in 517 (5·9%) participants. After excluding 121 participants with three most common causes of anaemia (chronic kidney disease, inflammation, iron deficiency), anaemia was found in 4·7% of euthyroid participants. Compared with the euthyroid group, the prevalence of anaemia was significantly higher in overt hyperthyroidism (14·6%, P < 0·01), higher with borderline significance in overt hypothyroidism (7·7%, P = 0·05) and not increased in subclinical thyroid dysfunction (5·0% in subclinical hypothyroidism, 3·3% in subclinical hyperthyroidism). Anaemia associated with thyroid dysfunction was mainly normocytic (94·0%), and rarely macrocytic (6·0%). CONCLUSION: The prevalence of anaemia was higher in overt hyperthyroidism, but not increased in subclinical thyroid dysfunction. Systematic measurement of thyroid-stimulating hormone in anaemic patients is likely to be useful only after excluding common causes of anaemia.
OBJECTIVE AND BACKGROUND: Anaemia and thyroid dysfunction are common and often co-occur. Current guidelines recommend the assessment of thyroid function in the work-up of anaemia, although evidence on this association is scarce. PATIENTS AND METHODS: In the 'European Prospective Investigation of Cancer' (EPIC)-Norfolk population-based cohort, we aimed to examine the prevalence and type of anaemia (defined as haemoglobin <13 g/dl for men and <12 g/dl for women) according to different thyroid function groups. RESULTS: The mean age of the 8791 participants was 59·4 (SD 9·1) years and 55·2% were women. Thyroid dysfunction was present in 437 (5·0%) and anaemia in 517 (5·9%) participants. After excluding 121 participants with three most common causes of anaemia (chronic kidney disease, inflammation, iron deficiency), anaemia was found in 4·7% of euthyroid participants. Compared with the euthyroid group, the prevalence of anaemia was significantly higher in overt hyperthyroidism (14·6%, P < 0·01), higher with borderline significance in overt hypothyroidism (7·7%, P = 0·05) and not increased in subclinical thyroid dysfunction (5·0% in subclinical hypothyroidism, 3·3% in subclinical hyperthyroidism). Anaemia associated with thyroid dysfunction was mainly normocytic (94·0%), and rarely macrocytic (6·0%). CONCLUSION: The prevalence of anaemia was higher in overt hyperthyroidism, but not increased in subclinical thyroid dysfunction. Systematic measurement of thyroid-stimulating hormone in anaemic patients is likely to be useful only after excluding common causes of anaemia.
Authors: Robert S Du Puy; Rosalinde K E Poortvliet; Simon P Mooijaart; David J Stott; Terry Quinn; Naveed Sattar; Rudi G J Westendorp; Patricia M Kearney; Vera J C McCarthy; Stephen Byrne; Nicolas Rodondi; Oliver Baretella; Tinh-Hai Collet; Diana van Heemst; Olaf M Dekkers; J Wouter Jukema; Johannes W A Smit; Jacobijn Gussekloo; Wendy P J den Elzen Journal: J Clin Endocrinol Metab Date: 2022-05-17 Impact factor: 6.134
Authors: Nicolien A van Vliet; Annelies E P Kamphuis; Wendy P J den Elzen; Gerard J Blauw; Jacobijn Gussekloo; Raymond Noordam; Diana van Heemst Journal: J Clin Endocrinol Metab Date: 2022-01-18 Impact factor: 5.958
Authors: Mijin Kim; Bo Hyun Kim; Hyungi Lee; Min Hee Jang; Jeong Mi Kim; Eun Heui Kim; Yun Kyung Jeon; Sang Soo Kim; In Joo Kim Journal: Endocrinol Metab (Seoul) Date: 2020-03